G
Giovanna Pomilio
Researcher at Monash University
Publications - 29
Citations - 2096
Giovanna Pomilio is an academic researcher from Monash University. The author has contributed to research in topics: Myeloid leukemia & Leukemia. The author has an hindex of 9, co-authored 27 publications receiving 1398 citations. Previous affiliations of Giovanna Pomilio include Alfred Hospital.
Papers
More filters
Journal ArticleDOI
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy,Szlávik Zoltán,James A. H. Murray,James Edward Paul Davidson,Ana Leticia Maragno,Gaëtane Le Toumelin-Braizat,Maïa Chanrion,Gemma L. Kelly,Gemma L. Kelly,Jia-Nan Gong,Jia-Nan Gong,Donia M Moujalled,Alain Bruno,Csékei Márton,Attila Paczal,Zoltán B. Szabó,Szabolcs Sipos,Gabor Radics,Proszenyák Ágnes,Balázs Bálint,Levente Ondi,Gábor Blasko,Alan P. Robertson,Allan E. Surgenor,Pawel Dokurno,Chen I-Jen,Natalia Matassova,Julia Smith,C. Pedder,Chris Graham,Aurélie Studeny,Gaëlle Lysiak-Auvity,Anne-Marie Girard,Fabienne Gravé,David J. Segal,David J. Segal,Chris D. Riffkin,Chris D. Riffkin,Giovanna Pomilio,Laura C. A. Galbraith,Laura C. A. Galbraith,Brandon J. Aubrey,Brandon J. Aubrey,Brandon J. Aubrey,Margs S. Brennan,Margs S. Brennan,Marco J Herold,Marco J Herold,Catherine Chang,Catherine Chang,Ghislaine Guasconi,Nicolas Cauquil,Fabien Melchiore,Nolwen Guigal-Stephan,Brian Lockhart,Frédéric Colland,John A. Hickman,Andrew W. Roberts,David C.S. Huang,David C.S. Huang,Andrew H. Wei,Andrew H. Wei,Andreas Strasser,Andreas Strasser,Guillaume Lessene,Guillaume Lessene,Olivier Geneste +66 more
TL;DR: It is demonstrated that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway.
Journal ArticleDOI
Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML.
Courtney D. DiNardo,Ing Soo Tiong,Ing Soo Tiong,A. Quaglieri,Sarah MacRaild,Sanam Loghavi,Fiona C. Brown,Rachel Thijssen,Giovanna Pomilio,Adam Ivey,Jessica M. Salmon,Christina Glytsou,Shaun Fleming,Shaun Fleming,Qi Zhang,Huaxian Ma,Keyur P. Patel,Steve Kornblau,Zhen Xu,Chong Chyn Chua,Chong Chyn Chua,Xufeng Chen,Piers Blombery,Piers Blombery,Piers Blombery,Christoffer Flensburg,Nik Cummings,Ioannis Aifantis,Hagop M. Kantarjian,David C.S. Huang,Andrew W. Roberts,Andrew W. Roberts,Ian J. Majewski,Marina Konopleva,Andrew H. Wei,Andrew H. Wei +35 more
TL;DR: Molecular determinants of outcome with clinical relevance to patients with AML receiving venetoclax-based combination therapies are identified, highlighting the dynamic and rapid occurrence of therapeutic selection in AML.
Journal ArticleDOI
AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies.
Sean Caenepeel,Sean P. Brown,Brian Belmontes,Gordon Moody,Kathleen S. Keegan,Danny Chui,Douglas A. Whittington,Xin Huang,Leszek Poppe,Alan C. Cheng,Mario G. Cardozo,Jonathan B. Houze,Yunxiao Li,Brian Lucas,Nick A. Paras,Xianghong Wang,Joshua Taygerly,Marc Vimolratana,Manuel Zancanella,Liusheng Zhu,Elaina Cajulis,Tao Osgood,Jan Sun,Leah J. Damon,Regina K. Egan,Patricia Greninger,Joseph McClanaghan,Jia-Nan Gong,Jia-Nan Gong,Donia M Moujalled,Giovanna Pomilio,Pedro J. Beltran,Cyril H. Benes,Andrew W. Roberts,David C.S. Huang,David C.S. Huang,Andrew H. Wei,Jude Canon,Angela Coxon,Paul E. Hughes +39 more
TL;DR: AMG 176 is a potent, selective, and orally bioavailable MCL1 inhibitor that induces a rapid commitment to apoptosis in models of hematologic malignancies and the synergistic combination of AMG 176 and venetoclax is synergistic in acute myeloid leukemia (AML) tumor models and in primary patient samples at tolerated doses.
Journal ArticleDOI
The caspase-8 inhibitor emricasan combines with the SMAC mimetic birinapant to induce necroptosis and treat acute myeloid leukemia.
Gabriela Brumatti,Gabriela Brumatti,Chunyan Ma,Chunyan Ma,Najoua Lalaoui,Najoua Lalaoui,Nhu Y. Nguyen,Mario Navarro,Maria C. Tanzer,Maria C. Tanzer,Jennifer Richmond,Margherita Ghisi,Jessica M. Salmon,Natasha Silke,Natasha Silke,Giovanna Pomilio,Stefan P Glaser,Stefan P Glaser,Elisha de Valle,Elisha de Valle,Raffi Gugasyan,Raffi Gugasyan,Mark A. Gurthridge,Stephen M. Condon,Ricky W. Johnstone,Richard B. Lock,Guy S. Salvesen,Andrew H. Wei,David L. Vaux,David L. Vaux,Paul G Ekert,Paul G Ekert,Paul G Ekert,John Silke,John Silke +34 more
TL;DR: It is shown that acute myeloid leukemia (AML) cells are sensitive to birinapant-induced death and that the clinical caspase inhibitor emricasan/IDN-6556 augments, rather than prevents, killing by birinAPant, which suggests that induction of necroptosis warrants clinical investigation as a therapeutic opportunity in AML.
Journal ArticleDOI
Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1
Tse-Chieh Teh,Tse-Chieh Teh,Nhu Y.N. Nguyen,Donia M Moujalled,David J. Segal,David J. Segal,Giovanna Pomilio,Sewa Rijal,Anissa Jabbour,K. Cummins,Kurt Lackovic,Kurt Lackovic,Piers Blombery,Ella R. Thompson,Paul G Ekert,Guillaume Lessene,Guillaume Lessene,Stefan P Glaser,Stefan P Glaser,David C.S. Huang,David C.S. Huang,Andrew W. Roberts,Mark A. Guthridge,Andrew H. Wei,Andrew H. Wei +24 more
TL;DR: It is shown that venetoclax synergizes with cytarabine and idarubicin to increase antileukemic efficacy in a TP53-dependent manner and should be investigated in combination with direct inhibitors of MCL1 as a chemotherapy-free approach in the future.